Biospecimen Unit

生物样本单元

基本信息

批准号：
10016227
负责人：
Kristina Ann Cole
金额：
$ 19.2万
依托单位：
CHILDREN'S HOSP OF PHILADELPHIA
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-09-30 至 2023-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10016227
关键词：
Architecture Atlases Autopsy B-Cell Acute Lymphoblastic Leukemia B-Lymphocytes Blood specimen Cells Cessation of life Child Childhood Childhood Glioma Chromatin Clinical Communities Data Analyses Databases Diagnosis Diagnostic radiologic examination Disease Ensure Evolution Genome Genomics Glioma Goals Human Human Resources Immune Immunotherapy In Situ Infrastructure Institution Knowledge Leadership Malignant Childhood Neoplasm Malignant Neoplasms Mission Modernization Molecular Neuroblastoma Oncologist Operative Surgical Procedures Pathologic Pathologist Patients Pediatric Neoplasm Process Recurrence Relapse Research Resistance Resolution Resource Sharing Role Sampling Space Perception Specimen Stream Structure Surgeon System Therapeutic Time Tissues Tumor Tissue Tumor-Associated Process biobank chemotherapy chimeric antigen receptor T cells data sharing high risk methylome multidisciplinary multiple omics neoplastic cell novel therapeutics prospective response standard of care success targeted treatment therapy development transcriptome tumor

项目摘要

Abstract The objective of the Biospecimen Unit is to provide the necessary infrastructure to prospectively acquire the highest quality human tumor specimens to support the mission of the Center for Pediatric Tumor Cell Atlas (CPTCA). Our existing biorepository infrastructure is modern, stream-lined and highly supported by our institution. Our leadership role in several similar, large scale multi-institutional projects have changed the therapeutic approach and standard of care of specific pediatric cancers and provide further evidence that the structure is already in place to ensure the success of CPTCA. We will prospectively collect tumor and blood samples from twenty patients for three major pediatric cancers. We propose the following three specific aims: 1) To acquire, process and characterize pediatric high-grade glioma biospecimens for the CPTCA examining the critical genomic transitions from diagnosis to relapse; 2) To acquire, process and characterize pediatric high-risk neuroblastoma biospecimens for the CPTCA to define tumor evolution and the clonal dynamic response to chemotherapy and targeted therapy; 3) To acquire, process and characterize pediatric very high-risk B-cell acute lymphoblastic leukemia (VHR ALL) biospecimens for the CPTCA for the evolution of disease through standard therapy and CAR-T cell immunotherapy. At the completion of this aim, we will provide high quality biospecimens to the Characterization Unit for comprehensive multi-omic and in situ analyses integrated with a highly annotated clinical, molecular, pathologic and radiographic database.

抽象的生物测量单元的目的是提供必要的基础设施前景获得最高质量的人类肿瘤标本以支持任务小儿肿瘤细胞图集（CPTCA）的中心。我们现有的生物座席基础设施是现代的，沿着我们的机构的高度支持。我们的在几个类似的大型多机构项目中的领导角色已经改变特定儿科癌症的治疗方法和护理标准并提供进一步的证据表明该结构已经存在，以确保CPTCA的成功。我们将前瞻性地收集20名患者的肿瘤和血液样本主要的儿科癌症。我们提出以下三个具体目标：1）获取， CPTCA的过程和特征的儿科高级神经胶质瘤生物测量检查从诊断到复发的关键基因组过渡； 2）获取，过程并表征儿科高危神经母细胞瘤生物测量 CPTCA定义肿瘤的演化以及对化学疗法的克隆动态反应和靶向治疗； 3）获取，过程和特征小儿非常高风险的B细胞 CPTCA的急性淋巴细胞白血病（VHR ALL）生物测量的进化通过标准疗法和CAR-T细胞免疫疗法进行疾病。完成在此目标中，我们将为特征单元提供高质量的生物测量。与高度注释的综合多摩变和原位分析临床，分子，病理和射线照相数据库。